{"id":44309,"date":"2022-05-25T05:01:25","date_gmt":"2022-05-25T03:01:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/"},"modified":"2022-05-25T05:01:25","modified_gmt":"2022-05-25T03:01:25","slug":"genexine-to-present-at-h-c-wainwright-global-investment-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/","title":{"rendered":"Genexine to Present at H.C. Wainwright Global Investment Conference"},"content":{"rendered":"
\n

SEOUL, South Korea–(BUSINESS WIRE)–Genexine (KOSDAQ: 095700), a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced that Neil Warma, CEO of Genexine will be presenting virtually at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.\n<\/p>\n

<\/a><\/p>\n

\nThe presentation will provide an overview of Genexine\u2019s pipeline, business operations and corporate achievements, as well as discuss upcoming milestones with the Company\u2019s lead assets, including GX-I7 (a first-in-class long-acting recombinant interleukin 7, in development for TNBC and GBM) and GX-188 (a first-in-class DNA vaccine, in development for cervical and head and neck cancers).\n<\/p>\n

\nDetails of the presentation are as follows:\n<\/p>\n

\nEvent:<\/strong> H.C. Wainwright Global Investment Conference
\n
Date & Time:<\/strong> On-demand, beginning 7.00 a.m. ET, Tuesday May 24, 2022
\n
Webcast Link:<\/b> Genexine_Wainwright_investor_conf.<\/a>\n<\/p>\n

\nA replay of the presentation will be available for 90 days at the link above or by visiting www.genexine.com<\/a>. Registered investors will be able to schedule a one-on-one meeting via the conference portal.\n<\/p>\n

\nAbout Genexine<\/b>\n<\/p>\n

\nGenexine, Inc. is a publicly traded, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technology platforms are Therapeutic DNA vaccine technology and hyFcTM<\/sup> fusion technology. The Company has multiple products in clinical development including several undergoing Phase 3 registrational trials. The Company’s proprietary pipeline includes GX-188 for cervical and head and neck cancer, GX-I7 for multiple cancers, GX-H9 for Pediatric Growth Hormone Deficiency and GX-E4 for CKD-induced anemia, among others. Genexine has established multiple partnerships with global companies in order to expedite product development and commercialization and create significant value. Genexine is listed on the Korean exchange (KOSDAQ: 095700) and is headquartered in Seoul, Korea. Genexine is committed to the well-being and care of patients worldwide.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor further information, please contact:
\n
Mr. Jongsoo Lee
\n
Investor Relations, Genexine, Inc.
\n
jongsoo.lee@genexine.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SEOUL, South Korea–(BUSINESS WIRE)–Genexine (KOSDAQ: 095700), a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced that Neil Warma, CEO of Genexine will be presenting virtually at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022. The … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44309","6":"format-standard","7":"category-industry"},"yoast_head":"\nGenexine to Present at H.C. Wainwright Global Investment Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genexine to Present at H.C. Wainwright Global Investment Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SEOUL, South Korea–(BUSINESS WIRE)–Genexine (KOSDAQ: 095700), a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced that Neil Warma, CEO of Genexine will be presenting virtually at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022. The ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-25T03:01:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220524006051\/en\/1466109\/21\/GENEXINE_CI.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexine-to-present-at-h-c-wainwright-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexine-to-present-at-h-c-wainwright-global-investment-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Genexine to Present at H.C. Wainwright Global Investment Conference\",\"datePublished\":\"2022-05-25T03:01:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexine-to-present-at-h-c-wainwright-global-investment-conference\\\/\"},\"wordCount\":327,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexine-to-present-at-h-c-wainwright-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220524006051\\\/en\\\/1466109\\\/21\\\/GENEXINE_CI.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexine-to-present-at-h-c-wainwright-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexine-to-present-at-h-c-wainwright-global-investment-conference\\\/\",\"name\":\"Genexine to Present at H.C. Wainwright Global Investment Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexine-to-present-at-h-c-wainwright-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexine-to-present-at-h-c-wainwright-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220524006051\\\/en\\\/1466109\\\/21\\\/GENEXINE_CI.jpg\",\"datePublished\":\"2022-05-25T03:01:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexine-to-present-at-h-c-wainwright-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexine-to-present-at-h-c-wainwright-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexine-to-present-at-h-c-wainwright-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220524006051\\\/en\\\/1466109\\\/21\\\/GENEXINE_CI.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220524006051\\\/en\\\/1466109\\\/21\\\/GENEXINE_CI.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexine-to-present-at-h-c-wainwright-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genexine to Present at H.C. Wainwright Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genexine to Present at H.C. Wainwright Global Investment Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Genexine to Present at H.C. Wainwright Global Investment Conference - Pharma Trend","og_description":"SEOUL, South Korea–(BUSINESS WIRE)–Genexine (KOSDAQ: 095700), a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced that Neil Warma, CEO of Genexine will be presenting virtually at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022. The ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-25T03:01:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220524006051\/en\/1466109\/21\/GENEXINE_CI.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Genexine to Present at H.C. Wainwright Global Investment Conference","datePublished":"2022-05-25T03:01:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/"},"wordCount":327,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220524006051\/en\/1466109\/21\/GENEXINE_CI.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/","url":"https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/","name":"Genexine to Present at H.C. Wainwright Global Investment Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220524006051\/en\/1466109\/21\/GENEXINE_CI.jpg","datePublished":"2022-05-25T03:01:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220524006051\/en\/1466109\/21\/GENEXINE_CI.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220524006051\/en\/1466109\/21\/GENEXINE_CI.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/genexine-to-present-at-h-c-wainwright-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Genexine to Present at H.C. Wainwright Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44309"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44309\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}